Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H6N2O2 |
Molecular Weight | 138.124 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C1=CNC=N1
InChI
InChIKey=LOIYMIARKYCTBW-OWOJBTEDSA-N
InChI=1S/C6H6N2O2/c9-6(10)2-1-5-3-7-4-8-5/h1-4H,(H,7,8)(H,9,10)/b2-1+
Molecular Formula | C6H6N2O2 |
Molecular Weight | 138.124 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Urocanic acid is a breakdown (deamination) product of histidine. In the liver, urocanic acid is an intermediate in the conversion of histidine to glutamic acid, whereas in the epidermis, it accumulates and may be both a UV protectant and an immunoregulator. Urocanic acid (UA) exists as a trans isomer (t-UA, approximately 30 mg/cm2) in the uppermost layer of the skin (stratum corneum). t-UA is formed as the cells of the second layer of skin become metabolically inactive. During this process, proteins and membranes degrade, histidine is released, and histidase (histidine ammonia lyase) catalyzes the deamination of histidine to form t-UA. t-UA accumulates in the epidermis until removal by either the monthly skin renewal cycle or sweat. Upon absorption of UV light, the naturally occurring t-UA isomerizes to its cis form, c-UA. Because DNA lesions (e. g. , pyrimidine dimers) in the lower epidermis can result from UV-B absorption, initial research proposed that t-UA acted as a natural sunscreen absorbing UV-B in the stratum corneum before the damaging rays could penetrate into lower epidermal zones. c-UA also suppresses contact hypersensitivity and delayed hypersensitivity, reduces the Langerhans cell count in the epidermis, prolongs skin-graft survival time, and affects natural killer cell activity. It has also been proposed that c-UA may mediate the transient alteration in immune surveillance resulting in immunosuppression induced after UV-irradiation, by interacting with immune cells locally and/or systemically to generate T cells with suppressor function.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
354.0 µM [IC50] | |||
Target ID: GO:0072608 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11601328 |
|||
Target ID: GO:0043303 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10325580 |
|||
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17085585 |
4.6 nM [Kd] |
PubMed
Title | Date | PubMed |
---|---|---|
Measurement of the skin urocanic acid content in normal and histidinemic infants. | 1983 Sep |
|
High-performance liquid chromatographic determination of (Z)-and (E)-urocanic acid in human skin. | 1984 Sep 14 |
|
Photochemistry and photobiology of urocanic acid. | 1985 Jun |
|
Urocanic acid concentration and photoisomerization in Caucasian skin phototypes. | 1997 May |
|
The potential role for urocanic acid and sunlight in the immune suppression associated with protein malnutrition. | 1998 Jul 10 |
|
Molecular mechanisms of cis-urocanic acid and permethrin-induced alterations in cutaneous immunity. | 2003 Dec |
|
Ring-substituted imidazoles as a new class of anti-tuberculosis agents. | 2004 Sep |
|
The effect of clinical UVA/B exposures on urinary urocanic acid isomer levels in individuals with caucasian type (II/III) skin types. | 2005 Dec 1 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11501667
A combination of the trans- and cis-isomers of urocanic acid (200 ug/ml) induced cAMP in both CD16+ and CD16- cells, but individual, stereospecific effects were not demonstrable.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:48:14 GMT 2023
by
admin
on
Fri Dec 15 19:48:14 GMT 2023
|
Record UNII |
G8D26XJJ3B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
104-98-3
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
ALTERNATIVE | |||
|
30817
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
203-258-4
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
3465-72-3
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
66357
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
DB01971
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
G8D26XJJ3B
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
UROCANIC ACID
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
736715
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
D014560
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY | |||
|
DTXSID5041148
Created by
admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
|